牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a company listed on The Nasdaq Capital Market under the symbol BDRX, has filed an amended Schedule 13G/A with the Securities and Exchange Commission on December 31, 2023. The filing indicates that Cavalry Fund I LP, Cavalry Fund I Management LLC, Cavalry Investment Fund LP, Cavalry Fund GP, LLC, and Thomas Walsh (collectively referred to as the Reporting Persons) have reported shared voting and dispositive power over 116,195,174 Ordinary Shares of Biodexa Pharmaceuticals, represented by 290,488 American Depositary Shares (ADSs). This figure includes shares issuable upon the exercise of warrants, subject to a 9.99% beneficial ownership blocker, which prevents the Reporting Persons from acquiring a beneficial ownership exceeding 9.99% of the company's outstanding Ordinary Shares. The Reporting Persons have disclaimed beneficial ownership of the securities except to the extent of their pecuniary interest. The address for the Reporting Persons is in Saddle River, New Jersey, and Thomas Walsh, as the Manager of Cavalry Fund I Management and the Managing Member of Cavalry Fund GP, may be deemed to beneficially own the securities reported.
Biodexa Pharmaceuticals PLC, a company listed on The Nasdaq Capital Market under the symbol BDRX, has filed an amended Schedule 13G/A with the Securities and Exchange Commission on December 31, 2023. The filing indicates that Cavalry Fund I LP, Cavalry Fund I Management LLC, Cavalry Investment Fund LP, Cavalry Fund GP, LLC, and Thomas Walsh (collectively referred to as the Reporting Persons) have reported shared voting and dispositive power over 116,195,174 Ordinary Shares of Biodexa Pharmaceuticals, represented by 290,488 American Depositary Shares (ADSs). This figure includes shares issuable upon the exercise of warrants, subject to a 9.99% beneficial ownership blocker, which prevents the Reporting Persons from acquiring a beneficial ownership exceeding 9.99% of the company's outstanding Ordinary Shares. The Reporting Persons have disclaimed beneficial ownership of the securities except to the extent of their pecuniary interest. The address for the Reporting Persons is in Saddle River, New Jersey, and Thomas Walsh, as the Manager of Cavalry Fund I Management and the Managing Member of Cavalry Fund GP, may be deemed to beneficially own the securities reported.
Biodexa Pharmicals PLC是一家在納斯達克資本市場上市，股票代碼爲BDRX的公司，已於2023年12月31日向美國證券交易委員會提交了經修訂的附表13G/A。文件顯示，Cavalry Fund I LP、Cavalry Fund I Management LLC、騎兵投資基金有限責任公司、騎兵基金GP, LLC和托馬斯·沃爾什（統稱爲申報人）報告了對Biodexa Pharmicals的116,195,174股普通股的共享投票權和處置權，這些普通股由290,488股美國存托股（ADS）代表。該數字包括在行使認股權證時可發行的股票，但受益所有權封鎖爲9.99％，這使申報人無法獲得超過公司已發行普通股9.99％的受益所有權。申報人已宣佈放棄對證券的實益所有權，但其金錢利益除外。申報人的地址位於新澤西州薩德爾裏弗，作爲騎兵基金一號管理經理和騎兵基金GP的管理成員的托馬斯·沃爾什可能被視爲受益擁有所報告的證券。
Biodexa Pharmicals PLC是一家在納斯達克資本市場上市，股票代碼爲BDRX的公司，已於2023年12月31日向美國證券交易委員會提交了經修訂的附表13G/A。文件顯示，Cavalry Fund I LP、Cavalry Fund I Management LLC、騎兵投資基金有限責任公司、騎兵基金GP, LLC和托馬斯·沃爾什（統稱爲申報人）報告了對Biodexa Pharmicals的116,195,174股普通股的共享投票權和處置權，這些普通股由290,488股美國存托股（ADS）代表。該數字包括在行使認股權證時可發行的股票，但受益所有權封鎖爲9.99％，這使申報人無法獲得超過公司已發行普通股9.99％的受益所有權。申報人已宣佈放棄對證券的實益所有權，但其金錢利益除外。申報人的地址位於新澤西州薩德爾裏弗，作爲騎兵基金一號管理經理和騎兵基金GP的管理成員的托馬斯·沃爾什可能被視爲受益擁有所報告的證券。
有用
沒用